Press Releases

All Releases

Summary Toggle Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases

Apr 11,2018

PDF Version

Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos , former CEO of ARIAD Pharmaceuticals through its 2017
...

Read more
Summary Toggle Arbutus to Present HBV Data at 2018 EASL Liver Meeting

Mar 28,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at the 53rd Annual International Liver Congress of the
...

Read more
Summary Toggle Arbutus Announces Corporate Update and Year-End 2017 Financial Results

Mar 14,2018

PDF Version

ARB-1467 Phase II Combination Study Beginning in 1Q18 Two New Drug Candidates Planned to Enter Clinical Development in 2H18 Over $200M in Cash Available to Fund Development of HBV Assets Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and...

Read more
Summary Toggle Arbutus Announces Conference Call to Provide a Corporate Update and Fourth Quarter 2017 Year-End Financial Results

Mar 12,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , March 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Wednesday, March 14, 2018 at 1:30 PM...

Read more
Summary Toggle Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology

Feb 22,2018

PDF Version

Acuitas has No Further Rights to Use or Sublicense Arbutus LNP Technology Arbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an...

Read more
Summary Toggle Arbutus Enters Exclusivity Agreement with Roivant Sciences

Feb 14,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Arbutus and Roivant entered into an exclusivity agreement (Exclusivity...

Read more
Summary Toggle Arbutus Announces Departure of Chief Financial Officer; Appoints Interim CFO

Feb 13,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Feb. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Bruce Cousins , Executive Vice President and Chief Financial Officer, is...

Read more
Summary Toggle Arbutus Consolidates HBV Business Around Warminster, PA Site

Feb 08,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a site consolidation and organizational restructuring to better align its HBV...

Read more
Summary Toggle Arbutus Announces Closing of the Second Tranche of a $116M Strategic Investment from Roivant Sciences

Jan 16,2018

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Jan. 16, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading hepatitis B virus (HBV) therapeutic solutions company, today announced the closing of the issue and sale of 664,000 series A participating convertible...

Read more
Summary Toggle Arbutus Announces Presentations at HepDART 2017

Nov 27,2017

PDF Version

VANCOUVER, British Columbia and WARMINSTER, Pa. , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced two oral presentations and one poster presentation at HepDART 2017 being held...

Read more